(Q36490252)

14 August 2017

Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers (English)

1 reference

14 August 2017

1 reference

Anton Leighton

1

1 reference

14 August 2017

Alice Bendix Gottlieb

2

1 reference

14 August 2017

Mary Beth Dorr

3

1 reference

14 August 2017

Daniela Jabes

4

1 reference

14 August 2017

Giorgio Mosconi

5

1 reference

14 August 2017

Claudia VanSaders

6

1 reference

14 August 2017

Edward J Mroszczak

7

1 reference

14 August 2017

Kathleen C M Campbell

8

1 reference

14 August 2017

Ellen Kelly

9

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

Antimicrobial Agents and Chemotherapy

14 August 2017

1 reference

14 August 2017

48

1 reference

14 August 2017

3

1 reference

14 August 2017

940-945

1 reference

Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353075

In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353075

Clinical pharmacokinetics of teicoplanin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353075

Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353075

Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353075

Antimicrobial resistance in staphylococci. Epidemiology, molecular mechanisms, and clinical relevance

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353075

Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353075

Audiologic monitoring for potential ototoxicity in a phase I clinical trial of a new glycopeptide antibiotic

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353075

In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353075

Methicillin-resistant Staphylococcus aureus in Europe

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/14982787

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/14982787

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.48.3.940-945.2004

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

14982787

1 reference